MLTX Q3 2024 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$32,515

Operating Income

-$43M

Net Income

-$35M

EPS (Diluted)

$-0.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$518M

Total Liabilities

$23M

Stockholders' Equity

$488M

Cash & Equivalents

$376M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$32,515	$0	—
Operating Income	-$43M	-$13M	-232.2%
Net Income	-$35M	-$9M	-275.5%

Revenue Segments

License

$300M100%